Get the Stockscreener App
183.98
0.20%
0.3391
Biogen Inc stock is traded at $183.98, with a volume of 178.94K.
It is up +0.20% in the last 24 hours and down -5.70% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$183.64
Open:
$182.63
24h Volume:
178.94K
Relative Volume:
0.12
Market Cap:
$27.01B
Revenue:
$9.53B
Net Income/Loss:
$1.29B
P/E Ratio:
20.89
EPS:
8.8057
Net Cash Flow:
$1.97B
1W Performance:
-0.69%
1M Performance:
-5.70%
6M Performance:
+33.66%
1Y Performance:
+29.95%
1-Day Range:
$180.33
$184.84
1-Week Range:
$180.33
$185.44
52-Week Range:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
184.01 | 26.95B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
902.39 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.87 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.89 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
184.99 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
115.81 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Inc. (NASDAQ:BIIB) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. Stock Stifel CNS Forum: $190 Target Price Driven by Tau Pipeline Pivot - TIKR.com
Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential - simplywall.st
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 - ACN Newswire
Swiss Life Asset Management Ltd Sells 21,970 Shares of Biogen Inc. $BIIB - MarketBeat
How Class Action Risks and Lupus Drug Advances Could Reframe Biogen's (BIIB) Innovation Narrative - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Lecanemab shows 67% patient retention at 24 months in US study - Investing.com
Why Biogen Inc. (BIIB) is a top value stock for the long term - MSN
Biogen Inc. stock gains momentum from pipeline advances and analyst upgrades amid biotech recovery - AD HOC NEWS
BIIB: High Persistence of Lecanemab Treatment in Real-World Anal - GuruFocus
Biogen unveils real-world data on early Alzheimer treatment persistence in U.S. - Traders Union
Eisai and Biogen Report High Treatment Persistence for Lecanemab in Real-World Alzheimer's Patients - Quiver Quantitative
Eli Lilly, Biogen/Eisai win UK review for use of Alzheimer’s drugs in NHS - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Eli Lilly (LLY) and Biogen (BIIB) Alzheimer's Drug Review by UK Watchdog - GuruFocus
U.K. to review use of Alzheimer’s drugs in NHS (LLY:NYSE) - Seeking Alpha
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
England to Review Rejection of Alzheimer’s Drugs for NHS - Bloomberg.com
PSA Biogas Upgrading Market Is Going to Boom | Biogen • Xebec Adsorption Inc. • Aqualia - openPR.com
Farmers Trust Co. Increases Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by AIA Group Ltd - MarketBeat
Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline - TipRanks
Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study - TipRanks
Biogen to present litifilimab data for cutaneous lupus at AAD - Investing.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - marketscreener.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - GlobeNewswire Inc.
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting - Biogen
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Insight Wealth Strategies LLC Buys Shares of 28,960 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans - MarketBeat
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's why Biogen Inc. (BIIB) is a strong momentum stock - MSN
Biogen at Stifel Forum: Strategic Insights on Alzheimer’s and Neuromuscular Advances - Investing.com
BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials - TradingView
Biogen Inc. (NASDAQ: BIIB) Q4 2025 earnings call transcript - MSN
HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII - GuruFocus
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says - MarketBeat
Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns - simplywall.st
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus - Yahoo Finance
Dow Update: Is Biogen Inc showing insider buying2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Gotham Asset Management Boosts Biogen Stake by 65% - National Today
Gotham Asset Management LLC Has $37.89 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Stock Holdings Boosted by Brevan Howard - National Today
Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
Behavioral Patterns of BIIB and Institutional Flows - Stock Traders Daily
Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB - MarketBeat
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Cinctive Capital Management LP Raises Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):